A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible pa...
A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient
About this item
Full title
Author / Creator
Publisher
London: Future Medicine Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
Programmed cell death-1 protein (PD-1) is an immune checkpoint that has gained popularity in the treatment of several advanced cancers. Inhibiting this checkpoint is known to enhance immune response, but is also known to diminish immune tolerance and to increase autoimmune toxicity. We discuss a case of rapid onset fulminant Type 1 diabetes induced...
Alternative Titles
Full title
A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2323429673
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2323429673
Other Identifiers
ISSN
1750-743X
E-ISSN
1750-7448
DOI
10.2217/imt-2017-0020
